Search

Your search keyword '"Pirrie, Sarah"' showing total 153 results
Start Over Author "Pirrie, Sarah"
153 results on '"Pirrie, Sarah"'

1. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Beesley, Richard, Churchill, Vicky, Insch, Elspeth, Loughton, Holly, MacDonald, Eilean, Lax, Siân, Lowe, Faye, Magwaro, Sophia, Gradwell, Mark, Kinsella, Francesca, Rolfe, Hayley, McIntyre, Stacey, Mortimer, Paige, Al-Taei, Saly, Tadros, Susan, Workman, Sarita, Arnott, Maxine, Brock, James, Melville, Andrew, Najm, Aurelie, Rutherford, Matthew, Sunzini, Flavia, Herman, Lou S, Hobbs, Agnieszka, Ragno, Martina, Wu, Mary Y, Selby, Rachael, Clay, Jennifer, Hutchison, Clare, Lown, Robert, Lwin, May N, Meardon, Naomi, Kelleher, Peter, Lightstone, Liz, Walters, Thomas, Denyer, Jayne, Ibrahim, Rahima, Gleeson, Sarah, Martin, Paul, McAdoo, Stephen, Baker, Helena, Horswill, Sarah, Parungao, Nina, Saich, Stephen, Cullinane, James, Irwin, Sophie, Klenerman, Paul, Marjot, Thomas, Chakraverty, Ronjon, Holroyd, Christopher, Kavi, Janki, Trown, Doreen, Babbage, Gavin, Chackathayil, Julia, Faria, Patricia, Ingham, Karen, Miah, Murad, Miranda, Mauro, O'Reilly, Nicola, Smith, Callie, Driver, Kimberley, Gauntlett, Kaylee, Farthing, Andrew, Rundell, Suzann, Smith, Emily, Tong, Andrew, Woolcock, Kieran, Hanke, Daniel, Laidlaw, Stephen, Malik, Zainab, Nguyen, Dung, Provine, Nicholas, Tipton, Tom, Walker, Victoria, Goodyear, Carl S, Patel, Amit, Barnes, Eleanor, Willicombe, Michelle, Siebert, Stefan, de Silva, Thushan I, Snowden, John A, Lim, Sean H, Bowden, Sarah J, Billingham, Lucinda, Richter, Alex, Carroll, Miles, Carr, Edward J, Beale, Rupert, Rea, Daniel, Parry, Helen, Pirrie, Sarah, Lim, Zixiang, Satsangi, Jack, Dunachie, Susanna J, Cook, Gordon, Miller, Paul, Basu, Neil, Gilmour, Ashley, Hodgkins, Anne-Marie, Evans, Lili, Hughes, Ana, Longet, Stephanie, Meacham, Georgina, Yong, Kwee L, A'Hearne, Matthew J, Koh, Mickey B C, Burns, Siobhan O, Orchard, Kim, Paterson, Caron, McIlroy, Graham, Murray, Sam M, Thomson, Tina, Dimitriadis, Stavros, Goulston, Lyndsey, Miller, Samantha, Keillor, Victoria, Prendecki, Maria, Thomas, David, Kirkham, Amanda, McInnes, Iain B, and Kearns, Pamela

Published
2024
Full Text
View/download PDF

2. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Author

Barnes, Eleanor, Goodyear, Carl S., Willicombe, Michelle, Gaskell, Charlotte, Siebert, Stefan, I de Silva, Thushan, Murray, Sam M., Rea, Daniel, Snowden, John A., Carroll, Miles, Pirrie, Sarah, Bowden, Sarah J., Dunachie, Susanna J., Richter, Alex, Lim, Zixiang, Satsangi, Jack, Cook, Gordon, Pope, Ann, Hughes, Ana, Harrison, Molly, Lim, Sean H., Miller, Paul, Klenerman, Paul, Basu, Neil, Gilmour, Ashley, Irwin, Sophie, Meacham, Georgina, Marjot, Thomas, Dimitriadis, Stavros, Kelleher, Peter, Prendecki, Maria, Clarke, Candice, Mortimer, Paige, McIntyre, Stacey, Selby, Rachael, Meardon, Naomi, Nguyen, Dung, Tipton, Tom, Longet, Stephanie, Laidlaw, Stephen, Orchard, Kim, Ireland, Georgina, Thomas, David, Kearns, Pamela, Kirkham, Amanda, and McInnes, Iain B.

Published
2023
Full Text
View/download PDF

6. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Goodyear, Carl S, primary, Patel, Amit, additional, Barnes, Eleanor, additional, Willicombe, Michelle, additional, Siebert, Stefan, additional, de Silva, Thushan I, additional, Snowden, John A, additional, Lim, Sean H, additional, Bowden, Sarah J, additional, Billingham, Lucinda, additional, Richter, Alex, additional, Carroll, Miles, additional, Carr, Edward J, additional, Beale, Rupert, additional, Rea, Daniel, additional, Parry, Helen, additional, Pirrie, Sarah, additional, Lim, Zixiang, additional, Satsangi, Jack, additional, Dunachie, Susanna J, additional, Cook, Gordon, additional, Miller, Paul, additional, Basu, Neil, additional, Gilmour, Ashley, additional, Hodgkins, Anne-Marie, additional, Evans, Lili, additional, Hughes, Ana, additional, Longet, Stephanie, additional, Meacham, Georgina, additional, Yong, Kwee L, additional, A'Hearne, Matthew J, additional, Koh, Mickey B C, additional, Burns, Siobhan O, additional, Orchard, Kim, additional, Paterson, Caron, additional, McIlroy, Graham, additional, Murray, Sam M, additional, Thomson, Tina, additional, Dimitriadis, Stavros, additional, Goulston, Lyndsey, additional, Miller, Samantha, additional, Keillor, Victoria, additional, Prendecki, Maria, additional, Thomas, David, additional, Kirkham, Amanda, additional, McInnes, Iain B, additional, Kearns, Pamela, additional, Beesley, Richard, additional, Churchill, Vicky, additional, Insch, Elspeth, additional, Loughton, Holly, additional, MacDonald, Eilean, additional, Lax, Siân, additional, Lowe, Faye, additional, Magwaro, Sophia, additional, Gradwell, Mark, additional, Kinsella, Francesca, additional, Rolfe, Hayley, additional, McIntyre, Stacey, additional, Mortimer, Paige, additional, Al-Taei, Saly, additional, Tadros, Susan, additional, Workman, Sarita, additional, Arnott, Maxine, additional, Brock, James, additional, Melville, Andrew, additional, Najm, Aurelie, additional, Rutherford, Matthew, additional, Sunzini, Flavia, additional, Herman, Lou S, additional, Hobbs, Agnieszka, additional, Ragno, Martina, additional, Wu, Mary Y, additional, Selby, Rachael, additional, Clay, Jennifer, additional, Hutchison, Clare, additional, Lown, Robert, additional, Lwin, May N, additional, Meardon, Naomi, additional, Kelleher, Peter, additional, Lightstone, Liz, additional, Walters, Thomas, additional, Denyer, Jayne, additional, Ibrahim, Rahima, additional, Gleeson, Sarah, additional, Martin, Paul, additional, McAdoo, Stephen, additional, Baker, Helena, additional, Horswill, Sarah, additional, Parungao, Nina, additional, Saich, Stephen, additional, Cullinane, James, additional, Irwin, Sophie, additional, Klenerman, Paul, additional, Marjot, Thomas, additional, Chakraverty, Ronjon, additional, Holroyd, Christopher, additional, Kavi, Janki, additional, Trown, Doreen, additional, Babbage, Gavin, additional, Chackathayil, Julia, additional, Faria, Patricia, additional, Ingham, Karen, additional, Miah, Murad, additional, Miranda, Mauro, additional, O'Reilly, Nicola, additional, Smith, Callie, additional, Driver, Kimberley, additional, Gauntlett, Kaylee, additional, Farthing, Andrew, additional, Rundell, Suzann, additional, Smith, Emily, additional, Tong, Andrew, additional, Woolcock, Kieran, additional, Hanke, Daniel, additional, Laidlaw, Stephen, additional, Malik, Zainab, additional, Nguyen, Dung, additional, Provine, Nicholas, additional, Tipton, Tom, additional, and Walker, Victoria, additional

Published
2024
Full Text
View/download PDF

7. Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action

Author

Nanton, Veronica, primary, Bryan, Richard T, additional, Pope, Anne M, additional, Hughes, Ana, additional, Jefferson, Kieran, additional, Catto, James W F, additional, Knight, Allen, additional, Gallagher, Jean, additional, Mintz, Harriet Paige, additional, Pirrie, Sarah J, additional, Liu, Wenyu, additional, Young, Annie, additional, Patel, Prashant, additional, and James, Nicholas D, additional

Published
2023
Full Text
View/download PDF

10. Abstract OT3-20-02: SMALL: Open Surgery versus Minimally invasive vacuum-Assisted excision for smaLL screen-detected breast cancer – a UK phase III randomised multi-centre trial

Author

McIntosh, Stuart A., primary, Coles, Charlotte E., additional, Dodwell, David, additional, Elder, Kenneth, additional, Foster, Jessica, additional, Gaunt, Claire, additional, Kirkham, Amanda, additional, Lyburn, Iain, additional, Morgan, Jenna, additional, Paramasivan, Sangeetha, additional, Pinder, Sarah E., additional, Pirrie, Sarah, additional, Potter, Shelley, additional, Roberts, Tracy, additional, Sharma, Nisha, additional, Stobart, Hilary, additional, Southgate, Elizabeth, additional, Taylor-Phillips, Sian, additional, Wallis, Matthew, additional, and Rea, Daniel, additional

Published
2023
Full Text
View/download PDF

11. Abstract P6-05-17: Recruitment challenges in a UK surgical de-escalation study: preliminary qualitative research findings from the SMALL trial

Author

McIntosh, Stuart A., primary, Coles, Charlotte E., additional, Dodwell, David, additional, Elder, Kenneth, additional, Foster, Jessica, additional, Gaunt, Claire, additional, Kirkham, Amanda, additional, Lyburn, Iain, additional, Morgan, Jenna, additional, Pinder, Sarah E., additional, Pirrie, Sarah, additional, Potter, Shelley, additional, Roberts, Tracy, additional, Sharma, Nisha, additional, Stobart, Hilary, additional, Southgate, Elizabeth, additional, Taylor-Phillips, Sian, additional, Wallis, Matthew, additional, Rea, Daniel, additional, and Paramasivan, Sangeetha, additional

Published
2023
Full Text
View/download PDF

12. Addressing overtreatment of screen detected DCIS; the LORIS trial

Author

Francis, Adele, Thomas, Jeremy, Fallowfield, Lesley, Wallis, Matthew, Bartlett, John M.S., Brookes, Cassandra, Roberts, Tracy, Pirrie, Sarah, Gaunt, Claire, Young, Jennie, Billingham, Lucinda, Dodwell, David, Hanby, Andrew, Pinder, Sarah E., Evans, Andrew, Reed, Malcolm, Jenkins, Valerie, Matthews, Lucy, Wilcox, Maggie, Fairbrother, Patricia, Bowden, Sarah, and Rea, Daniel

Published
2015
Full Text
View/download PDF

13. Additional file 1 of Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

Author

Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine A., Rea, Daniel, and Bartlett, John M. S.

Abstract

Additional file 1. Figure 1: DFI Benefit From 10 vs 5 y Tamoxifen is associated with increasing BCI (H/I) Levels. Figure 2: DFS benefit from 10 vs 5 y Tamoxifen is associated with increasing BCI (H/I) levels. Figure 3: Extended endocrine benefit from 10 vs 5 y Tamoxifen is not associated with Allred scores of ER, PR, or AR , or expression of ER or PR mRNA. Figure 4. Extended endocrine benefit from 10 vs 5 y Tamoxifen in the overall HR+ cohort (n=2,445). Table 1: BCI is prognostic for late distant recurrence

Published
2023
Full Text
View/download PDF

14. Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial

Author

Goodyear, Carl S., primary, Patel, Amit, additional, Barnes, Eleanor, additional, willicombe, michelle, additional, Siebert, Stefan, additional, de Silva, Thushan I., additional, Snowden, John A., additional, Lim, Sean, additional, Bowden, Sarah, additional, Billingham, Lucinda J., additional, Richter, Alex G., additional, Carroll, Miles W., additional, Carr, Edward J., additional, Beale, Rupert, additional, Rea, Daniel, additional, Parry, Helen, additional, Pirrie, Sarah, additional, Lim, Zixiang, additional, Satsangi, Jack, additional, Dunachie, Susanna, additional, Cook, Gordon, additional, Miller, Paul, additional, Basu, Neil, additional, Gilmour, Ashley, additional, Hodgkins, Anne-Marie, additional, Evans, Lili, additional, Hughes, Ana, additional, Longet, Stephanie, additional, Meacham, Georgina, additional, Yong, Kwee, additional, Ahearne, Matthew, additional, Koh, Mickey B. C., additional, Burns, Siobhan O., additional, Orchard, Kim, additional, Paterson, Caron, additional, McIlroy, Graham, additional, Murray, Sam M., additional, Thomson, Tina, additional, Dimitriadis, Stavros, additional, Goulston, Lyndsey, additional, Miller, Samantha, additional, Keillor, Victoria, additional, Prendecki, Maria, additional, Thomas, David, additional, Kirkham, Amanda, additional, McInnes, Iain, additional, and Kearns, Pamela, additional

Published
2023
Full Text
View/download PDF

17. SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancers.

Author

McIntosh, Stuart, primary, Coles, Charlotte E., additional, Conefrey, Carmel, additional, Dodwell, David John, additional, Foster, Jessica, additional, Gaunt, Claire, additional, Kirkham, Amanda, additional, Lyburn, Iain, additional, Morgan, Jenna, additional, Paramasivan, Sangeetha, additional, Pinder, Sarah E., additional, Pirrie, Sarah, additional, Potter, Shelley, additional, Roberts, Tracy, additional, Sharma, Nisha, additional, Stobart, Hilary, additional, Southgate, Elizabeth, additional, Taylor-Phillips, Sian, additional, Wallis, Matthew, additional, and Rea, Dan, additional

Published
2022
Full Text
View/download PDF

18. Visualising harms in publications of randomised controlled trials: consensus and recommendations

Author

Phillips, Rachel, primary, Cro, Suzie, additional, Wheeler, Graham, additional, Bond, Simon, additional, Morris, Tim P, additional, Creanor, Siobhan, additional, Hewitt, Catherine, additional, Love, Sharon, additional, Lopes, Andre, additional, Schlackow, Iryna, additional, Gamble, Carrol, additional, MacLennan, Graeme, additional, Habron, Chris, additional, Gordon, Anthony C, additional, Vergis, Nikhil, additional, Li, Tianjing, additional, Qureshi, Riaz, additional, Everett, Colin C, additional, Holmes, Jane, additional, Kirkham, Amanda, additional, Peckitt, Clare, additional, Pirrie, Sarah, additional, Ahmed, Norin, additional, Collett, Laura, additional, and Cornelius, Victoria, additional

Published
2022
Full Text
View/download PDF

19. Abstract OT1-06-02: SMALL - Open surgery versus minimally invasive vacuum-assisted excision for small screen detected breast cancer: A phase 3 randomised trial

Author

McIntosh, Stuart A, primary, Coles, Charlotte E, additional, Conefrey, Carmel, additional, Dodwell, David, additional, Elder, Kenneth, additional, Foster, Jessica, additional, Gaunt, Claire, additional, Kirkham, Amanda, additional, Lyburn, Iain, additional, Morgan, Jenna, additional, Paramasivan, Sangeetha, additional, Pinder, Sarah, additional, Pirrie, Sarah, additional, Potter, Shelley, additional, Roberts, Tracy, additional, Sharma, Nisha, additional, Stobart, Hilary, additional, Southgate, Elizabeth, additional, Taylor-Phillips, Sian, additional, Wallis, Matthew, additional, and Rea, Daniel, additional

Published
2022
Full Text
View/download PDF

20. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study

Author

Bartlett, John M.S., primary, Sgroi, Dennis C., additional, Treuner, Kai, additional, Zhang, Yi, additional, Piper, Tammy, additional, Salunga, Ranelle C., additional, Ahmed, Ikhlaaq, additional, Doos, Lucy, additional, Thornber, Sarah, additional, Taylor, Karen J., additional, Brachtel, Elena F., additional, Pirrie, Sarah J., additional, Schnabel, Catherine A., additional, and Rea, Daniel W., additional

Published
2022
Full Text
View/download PDF

21. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial

Author

James, Nicholas D., Pirrie, Sarah J., Pope, Ann M., Barton, Darren, Andronis, Lazaros, Goranitis, Ilias, Collins, Stuart, Daunton, Adam, McLaren, Duncan, O’Sullivan, Joe, Parker, Christopher, Porfiri, Emilio, Staffurth, John, Stanley, Andrew, Wylie, James, Beesley, Sharon, Birtle, Alison, Brown, Janet, Chakraborti, Prabir, Hussain, Syed, Russell, Martin, and Billingham, Lucinda J.

Published
2016
Full Text
View/download PDF

23. Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial

Author

Rea, Daniel, Francis, Adele, Wallis, Matthew, Thomas, Jeremy, Bartlett, John, Bowden, Sarah, Dodwell, David, Fallowfield, Lesley, Gaunt, Claire, Hanby, Andrew, Jenkins, Valerie, Matthews, Lucy, Pinder, Sarah, Pirrie, Sarah, Reed, Malcolm, Wilcox, Margaret, Roberts, Tracy, Kirwan, Cliona, Brookes, Cassandra, Fairbrother, Patricia, Billingham, Lucinda, Evans, Andrew, and Young, Jennie

Published
2017
Full Text
View/download PDF

24. TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer.

Author

James, Nicholas D., Liu, Wenyu, Pirrie, Sarah, Kaur, Baljit, Hendron, Carey, Ford, Daniel, Zarkar, Anjali, Viney, Richard, Southgate, Elizabeth, Desai, Amisha, Hussain, Syed A., Barber, Jim, Syndikus, Isabel, Malik, Zafar, Eswar, Chinnamani, Mangar, Stephen, Money‐Kyrle, Julian, Lydon, Anna, Van Der Voet, Johannes, and James, Nicholas

Subjects
CANCER invasiveness, CETUXIMAB, BLADDER cancer, CHEMORADIOTHERAPY, NEOADJUVANT chemotherapy
Abstract

Objective: To assess the feasibility and preliminary efficacy of adding cetuximab to standard chemoradiotherapy for muscle‐invasive bladder cancer. Patients and Methods: TUXEDO was a prospective, single‐arm, open‐label, phase I/II trial conducted in six UK hospitals. Cetuximab was administered with an initial loading dose of 400 mg/m2 on Day 1 of Week −1, and then seven weekly doses of 250 mg/m2. The radiotherapy schedule was 64 Gy/32F with Day 1 mitomycin C (12 g/m2) and 5‐fluorouracil (500 mg/m2/day) over Days 1–5 and Days 22–26. Patients with T2‐4aN0M0 urothelial cancer and a performance status of 0–1 were eligible. Prior neoadjuvant therapy was permitted. The Phase I primary outcome was impact on radiotherapy treatment completion and toxicity experienced during treatment. The Phase II primary outcome was local control at 3 months post treatment. Results: Between September 2012 and October 2016, 33 patients were recruited; seven in Phase I, 26 in Phase II. Three patients in Phase II were subsequently deemed ineligible and received no trial therapy. Eight patients discontinued cetuximab due to adverse effects. The patients' median (range) age was 70.1 (60.6–75.1) years, 20 had a performance status of 0, 27 were male and 26 had already received neoadjuvant chemotherapy. In Phase I, all patients completed planned radiotherapy, with no delays or dose reductions. Of the 30 evaluable patients in Phase II, 25 had confirmed local control 3 months after treatment (77%, 95% confidence interval 58–90). During the trial there were 18 serious adverse events. The study was halted due to slow accrual. Conclusion: Phase I data demonstrate it is feasible and safe to add cetuximab to chemoradiotherapy. Exploratory analysis of Phase II data provides evidence to consider further clinical evaluation of cetuximab in this setting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Urine DNA for monitoring chemoradiotherapy response in muscle‐invasive bladder cancer: a pilot study

Author

Gordon, Naheema S., primary, Baxter, Laura A., additional, Goel, Anshita, additional, Arnold, Roland, additional, Kaur, Baljit, additional, Liu, Wenyu, additional, Pirrie, Sarah J., additional, Hussain, Syed, additional, Viney, Richard, additional, Ford, Daniel, additional, Zarkar, Anjali, additional, Wood, Mary A., additional, Mitin, Timur, additional, Thompson, Reid F., additional, James, Nicholas D., additional, Ward, Douglas G., additional, and Bryan, Richard T., additional

Published
2021
Full Text
View/download PDF

27. Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer

Author

Chrysostomou, Stelios, primary, Roy, Rajat, additional, Prischi, Filippo, additional, Thamlikitkul, Lucksamon, additional, Chapman, Kathryn L., additional, Mufti, Uwais, additional, Peach, Robert, additional, Ding, Laifeng, additional, Hancock, David, additional, Moore, Christopher, additional, Molina-Arcas, Miriam, additional, Mauri, Francesco, additional, Pinato, David J., additional, Abrahams, Joel M., additional, Ottaviani, Silvia, additional, Castellano, Leandro, additional, Giamas, Georgios, additional, Pascoe, Jennifer, additional, Moonamale, Devmini, additional, Pirrie, Sarah, additional, Gaunt, Claire, additional, Billingham, Lucinda, additional, Steven, Neil M., additional, Cullen, Michael, additional, Hrouda, David, additional, Winkler, Mathias, additional, Post, John, additional, Cohen, Philip, additional, Salpeter, Seth J., additional, Bar, Vered, additional, Zundelevich, Adi, additional, Golan, Shay, additional, Leibovici, Dan, additional, Lara, Romain, additional, Klug, David R., additional, Yaliraki, Sophia N., additional, Barahona, Mauricio, additional, Wang, Yulan, additional, Downward, Julian, additional, Skehel, J. Mark, additional, Ali, Maruf M.U., additional, Seckl, Michael J., additional, and Pardo, Olivier E., additional

Published
2021
Full Text
View/download PDF

28. The endurance of children's working memory: A recall time analysis

Author

Towse, John N., Hitch, Graham J., Hamilton, Z., and Pirrie, Sarah

Subjects
Short-term memory -- Analysis, Family and marriage, Psychology and mental health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jecp.2008.03.009 Byline: John N. Towse (a), Graham J. Hitch (b), Z. Hamilton (c), Sarah Pirrie (a) Keywords: Working memory Abstract: We analyze the timing of recall as a source of information about children's performance in complex working memory tasks. A group of 8-year-olds performed a traditional operation span task in which sequence length increased across trials and an operation period task in which processing requirements were extended across trials of constant sequence length. Interword pauses were longer than are commonly found in immediate serial recall tasks yet shorter than for reading span. These pauses increased with the demands of recall, decreased across the output sequence, and were to some extent predictive of scholastic ability. Overall, timing data illustrate that recall in working memory tasks involves subtle processes of item access rather than simple readout of information from an immediate store. Author Affiliation: (a) Department of Psychology, Lancaster University, Lancaster LA1 4YF, UK (b) Department of Psychology, University of York, York YO10 5DD, UK (c) Department of Psychology, Royal Holloway University of London, Surrey TW20 0EX, UK Article History: Received 10 September 2007; Revised 31 March 2008

Published
2008

29. Abstract GS4-09: Correlative studies of the breast cancer index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: A trans-aTTom study

Author

Sgroi, Dennis C, primary, Treuner, Kai, additional, Zhang, Yi, additional, Piper, Tammy, additional, Salunga, Ranelle, additional, Ahmed, Ikhlaaq, additional, Doos, Lucy, additional, Thornber, Sarah, additional, Taylor, Karen J, additional, Brachtel, Elena F, additional, Pirrie, Sarah, additional, Schnabel, Catherine A, additional, Rea, Daniel W, additional, and Bartlett, John MS, additional

Published
2021
Full Text
View/download PDF

30. Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

Author

Kearns, Pamela, primary, Siebert, Stefan, additional, willicombe, michelle, additional, Gaskell, Charlotte, additional, Kirkham, Amanda, additional, Pirrie, Sarah, additional, Bowden, Sarah, additional, Magwaro, Sophia, additional, Hughes, Ana, additional, Lim, Zixiang, additional, Dimitriadis, Stavros, additional, Murray, Sam M., additional, Marjot, Thomas, additional, Win, Zay, additional, Irwin, Sophie L., additional, Meacham, Georgina, additional, Richter, Alex G., additional, Kelleher, Peter, additional, Satsangi, Jack, additional, Miller, Paul, additional, Rea, Daniel, additional, Cook, Gordon, additional, Turtle, Lance, additional, Klenerman, Paul, additional, Dunachie, Susanna, additional, Basu, Neil, additional, de Silva, Thushan I., additional, Thomas, David, additional, Barnes, Eleanor, additional, Goodyear, Carl S., additional, and McInnes, Iain, additional

Published
2021
Full Text
View/download PDF

31. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

Author

Gibb, Adam, primary, Pirrie, Sarah J., additional, Linton, Kim, additional, Warbey, Victoria, additional, Paterson, Kathryn, additional, Davies, Andrew J., additional, Collins, Graham P., additional, Menne, Tobias, additional, McKay, Pamela, additional, Fields, Paul A., additional, Miall, Fiona M., additional, Nagy, Eszter, additional, Wheatley, Keith, additional, Reed, Rachel, additional, Baricevic‐Jones, Ivona, additional, Barrington, Sally, additional, and Radford, John, additional

Published
2020
Full Text
View/download PDF

32. HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial.

Author

Bartlett, John, primary, Sgroi, Dennis C., additional, Treuner, Kai, additional, Zhang, Yi, additional, Piper, Tammy, additional, Salunga, Ranelle C., additional, Ahmed, Ikhlaaq, additional, Doos, Lucy, additional, Thornber, Sarah, additional, Taylor, Karen J., additional, Brachtel, Elena F., additional, Pirrie, Sarah, additional, Schnabel, Catherine A., additional, and Rea, Daniel William, additional

Published
2020
Full Text
View/download PDF

33. Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath study.

Author

James, Nicholas D., primary, Pirrie, Sarah, additional, Liu, Wenyu, additional, Amir, Rashid, additional, Gallagher, Jean, additional, Hughes, Ana, additional, Jefferson, Kieran, additional, Knight, Allen, additional, Nanton, Veronica, additional, Mintz, Harriet Paige, additional, Pope, Ann, additional, Catto, James WF, additional, Patel, Prashant, additional, and Bryan, Richard T., additional

Published
2020
Full Text
View/download PDF

35. Abstract P2-11-02: Breast Cancer Index predicts benefit from extended endocrine therapy in HR+ breast cancer

Author

Bartlett, John, primary, Sgori, Dennis, additional, Treuner, Kai, additional, Zhang, Yi, additional, Piper, Tammy, additional, Shalunga, Ranelle, additional, Ahmed, Ikhlaaq, additional, Doos, Lucy, additional, Thornber, Sarah, additional, Brachtel, Elena, additional, Pirrie, Sarah, additional, Schnabel, Catherine, additional, and Rea, Daniel, additional

Published
2020
Full Text
View/download PDF

36. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification

Author

Ward, Douglas G., Gordon, Naheema S., Boucher, Rebecca H., Pirrie, Sarah J., Baxter, Laura, Ott, Sascha, Silcock, Lee, Whalley, Celina M., Stockton, Joanne D., Beggs, Andrew D., Griffiths, Mike, Abbotts, Ben, Ijakipour, Hanieh, Latheef, Fathimath N., Robinson, Robert A., White, Andrew J., James, Nicholas D., Zeegers, Maurice P., Cheng, K. K., Bryan, Richard T., Complexe Genetica, RS: NUTRIM - R3 - Respiratory & Age-related Health, and RS: CAPHRI - R5 - Optimising Patient Care

Subjects
Adult, Male, CARCINOMA, diagnosis, BIOMARKERS, detection, GUIDELINES, Risk Assessment, #blcsm, Databases, Genetic, Humans, RECURRENCE, Aged, Aged, 80 and over, Carcinoma, Transitional Cell, #BladderCancer, High-Throughput Nucleotide Sequencing, DNA, DNA, Neoplasm, Sequence Analysis, DNA, Middle Aged, mutations, Prognosis, urine, TERT PROMOTER MUTATIONS, Urinary Bladder Neoplasms, Mutation, Translational Science, Female, LIQUID BIOPSIES
Abstract

Objectives To develop a focused panel of somatic mutations (SMs) present in the majority of urothelial bladder cancers (UBCs), to investigate the diagnostic and prognostic utility of this panel, and to compare the identification of SMs in urinary cell-pellet (cp)DNA and cell-free (cf)DNA as part of the development of a non-invasive clinical assay. Patients and Methods A panel of SMs was validated by targeted deep-sequencing of tumour DNA from 956 patients with UBC. In addition, amplicon and capture-based targeted sequencing measured mutant allele frequencies (MAFs) of SMs in 314 urine cpDNAs and 153 urine cfDNAs. The association of SMs with grade, stage, and clinical outcomes was investigated by univariate and multivariate Cox models. Concordance between SMs detected in tumour tissue and cpDNA and cfDNA was assessed. Results The panel comprised SMs in 23 genes: TERT (promoter), FGFR3, PIK3CA, TP53, ERCC2, RHOB, ERBB2, HRAS, RXRA, ELF3, CDKN1A, KRAS, KDM6A, AKT1, FBXW7, ERBB3, SF3B1, CTNNB1, BRAF, C3orf70, CREBBP, CDKN2A, and NRAS; 93.5-98.3% of UBCs of all grades and stages harboured >= 1 SM (mean: 2.5 SMs/tumour). RAS mutations were associated with better overall survival (P = 0.04). Mutations in RXRA, RHOB and TERT (promoter) were associated with shorter time to recurrence (P 94% of tumour SMs were detected in both cpDNA and cfDNA. Conclusions SMs are reliably detected in urinary cpDNA and cfDNA. The technical capability to identify very low MAFs is essential to reliably detect UBC, regardless of the use of cpDNA or cfDNA. This 23-gene panel shows promise for the non-invasive diagnosis and risk stratification of UBC.

Published
2019

37. DISSEMINATING PUBLISHING EXCELLENCE: THE 2021 AWAPAS.

Author

Ennis, Helen, Grishin, Sasha, Gaston, Robert, Palmer, Sheridan, Tello, Veronica, Nainby, Bryony, Foley, Fiona, Fitzgerald, Michael, Ellis, Ngarino, McDonald, Helen, Read, Richard, McNamara, Andrew, Pirrie, Sarah, Barrkman, Joanna, Garden, Wendy, Hall, Karen, Quin, Sally, and Larsson, Chari

Subjects
LITERARY prizes, ART literature awards, ART associations, LITERATURE
Abstract

The article announces the winners of the 2021 Art Writing and Publishing Awards (AWAPA) from Art Association of Australia and New Zealand (AANZ) like the Best Book award to "Billy Apple Life/Work" by Christina Barton, and Best Anthology to the book edited by Tony Bennett, Tamara Winikoff and Fred Myers.

Published
2022

38. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

Author

Gibb, Adam, Pirrie, Sarah J., Linton, Kim, Warbey, Victoria, Paterson, Kathryn, Davies, Andrew J., Collins, Graham P., Menne, Tobias, McKay, Pamela, Fields, Paul A., Miall, Fiona M., Nagy, Eszter, Wheatley, Keith, Reed, Rachel, Baricevic‐Jones, Ivona, Barrington, Sally, and Radford, John

Subjects
*HODGKIN'S disease, *COMPUTED tomography, *POSITRON emission tomography, *OLDER patients, *DRUG efficacy
Abstract

Summary: Standard treatment for classical Hodgkin lymphoma (cHL) is poorly tolerated in older patients and results disappointing. We assessed safety and efficacy of brentuximab vedotin (BV), in previously untreated patients with cHL unfit for standard treatment due to age, frailty or comorbidity. The primary outcome was complete metabolic response (CMR) by positron emission tomography/computed tomography after four BV cycles (PET4). The secondary outcomes included progression‐free survival (PFS), overall survival (OS), and toxicity. In all, 35 patients with a median age of 77 years and median total Cumulative Illness Rating Scale for Geriatrics (CIRS‐G) score of 6 were evaluable for toxicity and 31 for response. A median of four cycles were given (range one–16). In all, 14 patients required dose reduction due to toxicity and 11 patients stopped treatment due to adverse events (AEs). A total of 716 AEs were reported, of which 626 (88%) were Grade 1/2 and 27 (77%) patients had at least one AE Grade ≥3. At PET4, CMR was 25·8% [95% confidence interval (CI) 13·7–42.2%] and objective response rate 83·9% (95% CI 63·7–90·8%). Median PFS was 7·3 months (95% CI 5·2–9·0), and OS 19·5 months. Our results suggest that BV monotherapy is tolerable but suboptimal in the front‐line therapy of elderly or comorbid patients with cHL. Combining BV with other agents may be more effective. Trial Registration: Clinicaltrials.gov identifier: NCT02567851. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.

Author

Terrisse, Safae, Karamouza, Eleni, Parker, Chris C., Sartor, A. Oliver, James, Nicholas D., Pirrie, Sarah, Collette, Laurence, Tombal, Bertrand F., Chahoud, Jad, Smeland, Sigbjørn, Erikstein, Bjørn, Pignon, Jean-Pierre, Fizazi, Karim, and Le Teuff, Gwénaël

Published
2020
Full Text
View/download PDF

40. Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study

Author

Jochems, Sylvia H.J., primary, van Osch, Frits H.M., additional, Reulen, Raoul C., additional, van Hensbergen, Mitch, additional, Nekeman, Duncan, additional, Pirrie, Sarah J., additional, Wesselius, Anke, additional, van Schooten, Frederik J., additional, James, Nicholas D., additional, Wallace, D. Michael A., additional, Bryan, Richard T., additional, Cheng, K.K., additional, and Zeegers, Maurice P., additional

Published
2018
Full Text
View/download PDF

41. A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer.

Author

Aarab Terrisse, Safae, primary, Parker, Chris C., additional, Eleni, Karamouza, additional, Sartor, A. Oliver, additional, James, Nicholas, additional, Pirrie, Sarah, additional, Collette, Laurence, additional, Tombal, Bertrand F., additional, Chahoud, Jad, additional, Smeland, Sigbjørn, additional, Erisktein, Bjørn, additional, Pignon, Jean-Pierre, additional, Fizazi, Karim, additional, and Le Teuff, Gwénaël, additional

Published
2018
Full Text
View/download PDF

42. Urine DNA for monitoring chemoradiotherapy response in muscle‐invasive bladder cancer: a pilot study.

Author

Gordon, Naheema S., Baxter, Laura A., Goel, Anshita, Arnold, Roland, Kaur, Baljit, Liu, Wenyu, Pirrie, Sarah J., Hussain, Syed, Viney, Richard, Ford, Daniel, Zarkar, Anjali, Wood, Mary A., Mitin, Timur, Thompson, Reid F., James, Nicholas D., Ward, Douglas G., and Bryan, Richard T.

Subjects
BLADDER cancer, CANCER invasiveness, CHEMORADIOTHERAPY, DNA, PILOT projects, URINE
Abstract

We undertook a pilot study to evaluate whether measuring common BC-associated mutations in urinary DNA can contribute to the monitoring of treatment responses in patients with organ-confined MIBC treated with curative intent. Abbreviations BC bladder cancer cpDNA chloroplast DNA MIBC muscle-invasive bladder cancer SNV single-nucleotide variant VAF variant allele frequency Accumulating evidence implies the utility of DNA-based urine biomarkers for initial detection of bladder cancer (BC) and surveillance of non-muscle-invasive BC [1,2]. In summary, two out of the four patients who relapsed (three local, one distant, 3-9 months after completing treatment) had undetectable urinary VAFs on treatment completion. [Extracted from the article]

Published
2022
Full Text
View/download PDF

43. Preliminary results of a phase II study of brentuximab vedotin using a response adapted design for the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY)

Author

Gibb, Adam, Pirrie, Sarah, Linton, Kim, Paterson, K, Davies, A, Collins, G, Menne, T, McKay , P, Miall, P, Nagy, E, Wheatley , K, Warbey, V, Barrington, S, and Radford, J

Subjects
Elderly, Frail, Manchester Cancer Research Centre, Antibody drug conjugate, ResearchInstitutes_Networks_Beacons/mcrc, Brentuximab vedotin, ResearchInstitutes_Networks_Beacons/03/03, Hodgkin lymphoma, Cancer
Abstract

P002: Introduction. Results of standard treatment for older patients (pts) withclassical Hodgkin lymphoma (cHL) are sub-optimal and alternativeapproaches are required. Brentuximab vedotin (BV) is a CD30 targetedantibody-drug conjugate which in the pivotal* phase 2 trial inrelapsed/refractory cHL produced an objective response rate of 75%,complete remission rate of 34% and manageable toxicity. BREVITY isa study of efficacy/tolerability of BV in older, frail or comorbid pts withpreviously untreated cHL. Methods. This was a phase II, Simon 2-stage,single arm study requiring 30 evaluable pts. Primary outcome was completemetabolic response rate (CMR, Deauville Score 1-3) by centrallyreviewed PET-CT after 4 cycles of BV. Secondary outcomes includedPFS, OS, toxicity and comorbidity assessment (CIRS-G). Inclusion criteriawere previously untreated cHL stage 2 (with B symptoms and/ormediastinal bulk) or stages 3/4 with cardiac/respiratory compromise(at any age) or an ECOG score 1-3 and considered unfit for standardchemotherapy (in pts ≥60 yrs). BV dose was 1.8 mg/kg every 3 weeks,reduced to 1.2 mg/kg for toxicity. Pts in CMR/PMR after 4 doses BVcontinued to a total of 16 cycles if CT and/or PET-CT every 4 cyclesconfirmed ongoing response. PFS/OS data is not mature. Results. 38 ptswere recruited Feb 2014-Oct 2015 at 12 UK centres; demographics areshown in Table 1.Table 1.35 pts were treated and evaluable for toxicity, 31 are evaluable forresponse. Median follow-up for alive pts is 11.6(range 0.9, 21.4) months.A median of 4 cycles were given per pt (range 1, 16). 28(12%) cycles in14 pts were modified due to toxicity and 11 pts stopped treatment dueto adverse events (AEs). 695 AEs were reported of which 601(86%)were grade 1/2. 26(74%) pts had at least 1 AE ≥grade 3, most commonlyinfection, myelosuppression or neuropathy. CMR rate at PET4 was25.8%(95% CI 13.7, 43.2) and combined CMR/PMR rate was83.7(95%CI: 67.4, 92.9). To date 21(67.7%) pts have progressed. Discussion.In this study BV monotherapy produced a high objectiveresponse rate although the CMR rate after 4 cycles did not meet thepre-specified 40% level. Toxicity was greater than in the pivotal* studywhere pts were younger/fitter and led to treatment termination in somepts. Nevertheless BV is effective in this older comorbid population. Afollow-on study incorporating BV at lower dose in combination withother agents and growth factor support aimed at improving the CMRrate is in development.

Published
2016

46. Designing a practice-changing trial for a rare cancer population: The Rational MCC trial of first definitive treatment for Merkel cell carcinoma

Author

Blundred, Rachel, primary, Yap, Christina, additional, Corner, Carie, additional, Lawton, Pat, additional, Cassell, Oliver, additional, McGarr, Clair, additional, Zealley, Ian, additional, Pirrie, Sarah, additional, Bowden, Sarah, additional, Babrah, Jaspreet, additional, Rodwell, Simon, additional, Harwood, Catherine, additional, and Steven, Neil, additional

Published
2016
Full Text
View/download PDF

47. Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

Author

Andronis, Lazaros, primary, Goranitis, Ilias, additional, Pirrie, Sarah, additional, Pope, Ann, additional, Barton, Darren, additional, Collins, Stuart, additional, Daunton, Adam, additional, McLaren, Duncan, additional, O'Sullivan, Joe M., additional, Parker, Chris, additional, Porfiri, Emilio, additional, Staffurth, John, additional, Stanley, Andrew, additional, Wylie, James, additional, Beesley, Sharon, additional, Birtle, Alison, additional, Brown, Janet E., additional, Chakraborti, Prabir, additional, Hussain, Syed A., additional, Russell, J. Martin, additional, Billingham, Lucinda J., additional, and James, Nicholas D., additional

Published
2016
Full Text
View/download PDF

48. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer

Author

James, Nicholas, primary, Pirrie, Sarah, additional, Pope, Ann, additional, Barton, Darren, additional, Andronis, Lazaros, additional, Goranitis, Ilias, additional, Collins, Stuart, additional, McLaren, Duncan, additional, O’Sullivan, Joe, additional, Parker, Chris, additional, Porfiri, Emilio, additional, Staffurth, John, additional, Stanley, Andrew, additional, Wylie, James, additional, Beesley, Sharon, additional, Birtle, Alison, additional, Brown, Janet, additional, Chakraborti, Prabir, additional, Russell, Martin, additional, and Billingham, Lucinda, additional

Published
2016
Full Text
View/download PDF

50. Artist with axes : the making of a resource as a contemporary environmental aesthetic

Author

Pirrie, Sarah

Abstract

This exegesis uses the metaphoric portrait of “artists with axes” to depict the artist as both creator and destroyer. As such, my position as an artist is established as residing between and within these societal binary opposites. Using the philosophical trajectory of Gilles Deleuze and Félix Guattari, I have established a practice which embraces the making process as an event and ongoing resource. This resourcing responds to multiplicity of envisioned Natures and a learning trajectory which includes materials found; materials produced, and an events based practice ‘(n)onsite’, in studio or gallery. Making a resource as a contemporary environmental aesthetic includes the ecological phenomenon of waste and the relational activity of recycling, the integration of past or present artistic production, and acts of graffiti which mimic or acknowledge processual concepts of environment. I directly respond to ecological thoughts about our environment within my local context, identifying my materials as a milieu relational to environmental conditions and responsive to change. Focus is given to my learning trajectory of paper/pulp. Using the materiality of paper I am able to explore the interface between the creation/destruction binaries, resulting in metaphoric dissolution or flow as each event dictates. As a resource paper is destined to be recycled but also has an association with its original organic properties which equally identifies it with environmental damage. For me, the physicality of paper combines with environmental conditions to express a direct connection with Nature. Throughout this candidature I have focused on several projects which I will discuss within this exegesis. These include: Names on Trees (NOT Project); an ongoing intervention with taggers of Eucalyptus trees at the Jingili Watergardens of Darwin, Temporary Fence Hire (TFH) an ongoing project using the common temporary fence to consider change within the environment. And be careful how you develop an installation at the Wesleyan Church, George Brown Botanic Gardens. In addition to these events I refer to my past projects such as Helen’s Wreath and LOW to emphasise the processual context past events have with future project.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results